[{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Biotechnologies \/ Adaptive Biotechnologies","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Biotechnologies \/ Adaptive Biotechnologies"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"||B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adaptive Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"||B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adaptive Biotechnologies \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Biotechnologies \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Adaptive Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adaptive Biotechnologies \/ Adaptive Biotechnologies","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Biotechnologies \/ Adaptive Biotechnologies"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adaptive Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Adaptive Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Biotechnologies \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"Adaptive Biotechnologies \/ Amgen Inc"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Biotechnologies \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Adaptive Biotechnologies \/ Genentech"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptive Biotechnologies","amount2":2.2999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":2.2999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Biotechnologies \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Adaptive Biotechnologies \/ Genentech"}]

Find Clinical Drug Pipeline Developments & Deals by Adaptive Biotechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The companies will wind down activities under the Agreement. Upon termination, Adaptive will be released from exclusivity obligations with respect to cell therapies in oncology.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : $300.0 million

                          August 18, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Genentech

                          Deal Size : $2,300.0 million

                          Deal Type : Termination

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Bendamustine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 16, 2024

                          Lead Product(s) : Bendamustine Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Fox Chase Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : U.S. Food and Drug Administration has accepted an investigational new drug (IND) application for a T-cell receptor (TCR) based T-Cell Therapy in oncology.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 09, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies including, TAK-007, a CD19 chimeric antigen receptor-directed cord blood derived natural k...

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          April 12, 2023

                          Lead Product(s) : TAK-007,Cyclophosphamide,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Tecartus/(KTE-X19 (brexucabtagene autoleucel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL).

                          Product Name : Tecartus

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          June 02, 2022

                          Lead Product(s) : Brexucabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : In the multinational phase 3 ENSEMBLE trial, participants given Johnson & Johnson’s vaccine experienced similar efficacy against the B.1.351 variant.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 09, 2021

                          Lead Product(s) : Ad26.COV2.S

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Venetoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 05, 2020

                          Lead Product(s) : Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Memorial Sloan Kettering Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The companies will combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 02, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : Amgen Inc

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank